Since the time–action profile of rapid-acting insulin better mimics endogenous insulin compared with regular human insulin (RHI), it has been assumed that rapid-acting insulin should be used in pumps for treating patients with diabetes. This evidence concerns the gene INS and diabetes mellitus.